BIOORGANIC & MEDICINAL CHEMISTRY, published by Pergamon-Elsevier Science Ltd, is a prominent journal in the fields of biochemical research and drug discovery, with an ISSN of 0968-0896 and an E-ISSN of 1464-3391. Established in 1993, it has garnered respect and recognition, evidenced by its categorization in various quartile ranks across 2023, including Q2 in Clinical Biochemistry and Pharmaceutical Science. It holds significant Scopus rankings, placing it in the 75th percentile in Pharmaceutical Science and 74th percentile in Organic Chemistry, highlighting its influential contributions to ongoing research and developments. This journal provides a platform for disseminating advancements in bioorganic and medicinal chemistry, focusing on innovative methodologies, therapeutic advancements, and molecular pharmacology. Although it does not follow an open-access model, it remains a key resource for researchers, professionals, and students aiming to stay at the forefront of scientific discovery in the UK and beyond. The journal’s commitment to enhancing knowledge within the biomedical community makes it an essential read for those passionate about this dynamic field.

ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES is a peer-reviewed journal published by Mary Ann Liebert, Inc., focused on the innovative fields of pharmacology and drug development. With its ISSN 1540-658X and E-ISSN 1557-8127, the journal has successfully contributed to the scientific community since its inception in 2002, converging into one comprehensive resource by 2024. Positioned in the Q3 quartile for Drug Discovery and Q4 for Molecular Medicine as per the 2023 rankings, the journal is dedicated to disseminating cutting-edge research that addresses the complexities of drug assay techniques and their implications in therapeutics. Although currently not an open-access publication, it offers significant insights and findings valuable to researchers, professionals, and students in the realm of biochemistry and pharmacology. With a commitment to advancing knowledge and innovation, ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES continues to be an essential platform for the latest advancements in drug discovery and development.

The Journal of Pharmaceutical and Biomedical Analysis, published by ELSEVIER and available in print and online formats, stands as a pivotal source of knowledge in the realms of Analytical Chemistry, Clinical Biochemistry, Drug Discovery, and Pharmaceutical Science. With an ISSN of 0731-7085 and an e-ISSN of 1873-264X, this journal is dedicated to publishing high-quality research that advances the understanding and development of analytical techniques in pharmaceuticals and biomedicine. The journal has earned a solid reputation, reflected in its Q2 category rankings across five distinct fields for 2023, and boasts impressive Scopus rankings, signaling its robust impact within the academic community. The Journal of Pharmaceutical and Biomedical Analysis serves as an essential resource for researchers, professionals, and students alike, providing actionable insights and fostering innovation that can directly influence future advancements in drug development and biomedical applications.

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

Pakistan Journal of Pharmaceutical Sciences, published by the University of Karachi, serves as a vital platform for advancing research in the field of pharmaceutical sciences. With a strong commitment to disseminating innovative findings and critical studies since its inception in 1995, the journal focuses on a wide array of topics including pharmacology, toxicology, and pharmaceutics. With an ISSN of 1011-601X, it holds a reputable position within the academic community, reflecting its Q3 category ranking in Pharmaceutical Science as of 2023. While the journal is currently not designated as Open Access, it remains accessible through institutional subscriptions, ensuring that both emerging and established researchers can contribute to and benefit from its scholarly content. This publication not only promotes scientific dialogue but also aims to bridge the gap between academia and industry, appealing to a diverse audience of researchers, professionals, and students seeking to stay informed about the latest advancements and trends in pharmaceutical research.

Pharmaceutical Chemistry Journal is a pivotal publication in the field of pharmaceutical sciences, renowned for its in-depth articles and research findings. Published by Springer in the United States, this journal provides a crucial platform for researchers, students, and professionals dedicated to advancing drug discovery and pharmacology. With an ISSN of 0091-150X and an E-ISSN of 1573-9031, this journal has consistently aimed to promote scholarly communication and innovation within its scope since its inception in 1967. Despite its current Category Quartiles ranking of Q4 in both Drug Discovery and Pharmacology, the journal remains a valuable resource for disseminating new ideas and findings that contribute to the scientific community. Researchers benefit from the journal's commitment to high-quality peer-reviewed content, even in an environment where open access options are currently not available. As the field evolves, the Pharmaceutical Chemistry Journal continues to play an important role in shaping future advancements in drug development and safety.

ACTA POLONIAE PHARMACEUTICA is a well-established peer-reviewed journal published by Polskie Towarzystwo Farmaceutyczne, dedicated to the field of pharmaceutical sciences and pharmacology. With a rich history dating back to 1951, this journal serves as a vital platform for disseminating cutting-edge research and developments in pharmaceutical technology, drug development, and therapeutic therapies. Although it currently operates under a subscription model, its commitment to scientific rigor has earned it a respectable impact factor, placing it in the Q3 and Q4 quartiles respectively for Pharmaceutical Science and Pharmacology as of 2023. Researchers and practitioners alike will find value in its comprehensive coverage of essential topics, as well as its diverse range of contributions from both established and emerging scholars in the field. With its address located in the heart of Warsaw, Poland, ACTA POLONIAE PHARMACEUTICA aims to further bridge the gap between academia and industry, paving the way for innovation in drug discovery and therapeutic applications.

Tropical Journal of Pharmaceutical Research is an esteemed open-access platform dedicated to advancing the field of pharmaceutical sciences, published by the Pharmacotherapy Group in Nigeria. With an ISSN of 1596-5996 and open access established since 2002, this journal serves as a critical resource for researchers, professionals, and students seeking to disseminate and access high-quality research in both pharmaceutical science and pharmacology. Despite its ranking in the third quartile (Q3) for Pharmaceutical Science and the fourth quartile (Q4) in Pharmacology as of 2023, the journal continues to stand out with its commitment to fostering significant dialogue and innovation in the scientific community. Anchored at the University of Benin, Faculty of Pharmacy, the journal invites contributions that explore novel pharmaceutical research, clinical applications, and drug development, playing a vital role in addressing health challenges that are particularly relevant to tropical regions. Researchers can look forward to publishing their findings in a journal that not only promotes the sharing of knowledge but also enhances the scientific discourse within a rapidly evolving field.

CURRENT PHARMACEUTICAL DESIGN is a leading journal in the fields of Drug Discovery and Pharmacology, published by Bentham Science Publishers Ltd in the dynamic United Arab Emirates. With an impressive historical span from 1995 to 2024, this journal serves as a vital platform for disseminating innovative research findings, breakthrough methodologies, and critical reviews that shape the future of pharmaceutical sciences. Ranked Q2 in both Drug Discovery and Pharmacology categories according to the 2023 metrics, it places itself within the top-tier percentile, catering to a diverse audience of researchers, industry professionals, and students. The journal’s commitment to high-quality research exploration is evidenced by its Scopus ranking, where it is positioned favorably within its category ranks. Although currently not Open Access, CURRENT PHARMACEUTICAL DESIGN remains an essential resource for those looking to stay at the forefront of pharmacological advancements and drug development strategies.

Chemical Biology & Drug Design, an esteemed publication by WILEY, serves as a vital platform for the dissemination of pioneering research in the interdisciplinary fields of biochemistry, drug discovery, molecular medicine, organic chemistry, and pharmacology. With a dedicated commitment to advancing the understanding of chemical interactions and drug development, this journal not only fosters innovation but also bridges the gap between theoretical research and practical applications. It boasts an impressive impact factor and is recognized in the 2023 category quartiles as Q3 in Biochemistry and Molecular Medicine, and Q2 in Drug Discovery, Organic Chemistry, and Pharmacology, indicating its relevance and influence in these crucial areas. The journal’s rankings across various Scopus categories further solidify its position as a reputable resource for researchers, professionals, and students striving to stay at the forefront of medicinal chemistry and drug design. While primarily traditional access-based, the journal's evolving scope from 2006 to 2024 ensures an ongoing contribution to essential scientific dialogue, making it an indispensable read for those committed to advancing health sciences.